Researchers have developed an in silico (computer) platform that couples tissue adaptation with cellular and molecular interactions to simulate bone adaptation to mechanical loading and progress and treatment of metabolic bone diseases. What is the benefit of such in silico tools, and how can credibility of the simulation outcomes be established?
This is a preview of subscription content, log in via an institution to check access.
References
Seeman, E. & Martin, T. J. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat. Rev. Rheumatol. 15, 225–236 (2019).
Kameo, Y., Miya, Y., Hayashi, M., Nakashima, T. & Adachi, T. In silico experiments of bone remodeling explore metabolic diseases and their drug treatment. Sci. Adv. 6, eaax0938 (2020).
Gerhard, F. A., Webster, D. J., van Lenthe, G. H. & Müller, R. In silico biology of bone modelling and remodelling: adaptation. Philos. Trans. A Math. Phys. Eng. Sci. 367, 2011–2030 (2009).
Riggs, M. M. & Cremers, S. Pharmacometrics and systems pharmacology for metabolic bone diseases. Br. J. Clin. Pharmacol. 85, 1136–1146 (2019).
US Food and Drug Administration. Reporting of Computational Modeling Studies in Medical Device Submissions https://www.fda.gov/regulatory-information/search-fda-guidance-documents/reporting-computational-modeling-studies-medical-device-submissions (2016).
The American Society of Mechanical Engineers. Assessing Credibility of Computational Modeling through Verification and Validation: Application to Medical Devices https://www.asme.org/codes-standards/find-codes-standards/v-v-40-assessing-credibility-computational-modeling-verification-validation-application-medical-devices (2018).
Kuemmel, C. et al. Consideration of a credibility assessment framework in model-informed drug development: potential application to physiologically-based pharmacokinetic modeling and simulation. CPT Pharmacometrics Syst. Pharmacol. 9, 21–28 (2020).
Musuamba, F. T. et al. Verifying and validating quantitative systems pharmacology and in silico models in drug development: current needs, gaps, and challenges. CPT Pharmacometrics Syst. Pharmacol. 9, 195–197 (2020).
Acknowledgements
The author gratefully acknowledges funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (ERC CoG 772418) and from EOS, the programme for Excellence of Science in Belgium supported by FNRS-FWO.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares there are no competing interests
Rights and permissions
About this article
Cite this article
Geris, L. In silico tools predict effects of drugs on bone remodelling. Nat Rev Rheumatol 16, 475–476 (2020). https://doi.org/10.1038/s41584-020-0457-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-020-0457-6
- Springer Nature Limited